Items Tagged ‘Mylotarg’

September 5, 2017

FDA Approves Mylotarg for Treatment of Acute Myeloid Leukemia


The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved Mylotarg for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, AML, CD33 antigen, gemtuzumab ozogamicin, Leukemia, Mylotarg, News, Precision Cancer Medicine, targeted therapy